Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bedaquiline-based regimen for treatment-refractory MAC lung disease
jRCT2031200268Phase 3Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Mar 2021
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, open-label trial of bedaquiline in Mycobacterium avium-intracellulare infection (MAI) (2 arms), sponsored by Janssen Pharmaceutical. Primary endpoint: Percentage of participants with sputum culture conversion in MGIT at Week 24. Started Mar 2021; status: completed.
02
Drugs
bedaquiline
03
Conditions
Mycobacterium avium-intracellulare infection (MAI)
Beyond the preview
Go deeper on jRCT2031200268.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031200268.